Marie Solgaard

Copenhagen University Hospital Hvidovre, Hvidovre, Capital Region, Denmark

Are you Marie Solgaard?

Claim your profile

Publications (2)0 Total impact

  • Source
    Niklas Rye, Marie Solgaard, Peter Schwarz
    [Show abstract] [Hide abstract]
    ABSTRACT: THE ROLE OF purinergic P2 receptors in bone biology has been evaluated over the last decade. These receptors have proven to be an interesting target for new pharmacological agents with the ability to regulate bone metabolism. As the prevalence of osteoporosis increases new efficient agents to treat the disease are sought for. The P2 receptors are activated by nucleotides and recently, studies have shown a possible role for these in bone turnover and metabolism. P2 receptors can be divided further into P2X and P2Y subtypes with strikingly different mechanisms of action. They are ex-pressed both by osteoblasts and by osteoclasts, and agonist binding affects cell proliferation, differentiation, activity, and apoptosis of the cells. With the increasingly knowledge of the function and role of these receptors in bone biology, they will undoubtedly be a potential target for designing new drugs, which can be used for treatment of metabolic bone diseases, including osteo-porosis. This article is reviewing the studies documenting the effects of nu-cleotides and P2 receptors in bone and bone cells.
    01/2006; 3.
  • Marie Solgaard, Niklas Rye Jørgensen
    [Show abstract] [Hide abstract]
    ABSTRACT: Osteoporosis is a disabling disease, and despite the progress in treating this disease in recent years, it is still necessary to develop new treatment options. A potential target for new pharmacological agents with the ability to regulate bone metabolism is the purinergic receptors, also called P2 receptors. Nucleotides activate these receptors, and recent studies have shown a possible role for these in bone turnover and metabolism. P2 receptors can be further divided into P2X and P2Y subtypes, which have strikingly different mechanisms of action. They are expressed both by osteoblasts and by osteoclasts, and agonist binding affects cell proliferation, differentiation, activity and apoptosis. With increasing knowledge of the function and role of these receptors in bone biology, they will undoubtedly be a future target for the design of new drugs which can be used for treatment of metabolic bone diseases, including osteoporosis.
    Ugeskrift for laeger 09/2005; 167(34):3152-6.

Publication Stats

1 Citation

Top Journals

Institutions

  • 2005–2006
    • Copenhagen University Hospital Hvidovre
      • Department of Clinical Biochemistry
      Hvidovre, Capital Region, Denmark